We are live on ! Find out more

Phathom Pharmaceuticals

PHAT

Market cap $605M

7.48 USD

-0.27

3.48%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

7.41

-0.07

0.94%

1 day

-3.48%

5 days

-11.48%

1 month

-19.14%

3 months

-31.25%

6 months

-31.75%

Year to date

-52.39%

1 year

-36.34%

5 years

-77.23%

10 years

-69.59%

About: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Employees: 371

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 16.7%

Neutral 83.3%

Negative 0%

PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $PHAT--PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law.

PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case

Phathom Pharmaceuticals is executing a specialist-focused strategy, targeting gastroenterologists to drive VOQUEZNA adoption and move toward sustainable profitability. Second-quarter 2026 revenue grew 88% to $74.3M, SG&A fell, and management forecasts 2026 revenue of $310–$325M with an 80% gross margin, signaling operating leverage. PHAT's commercial runway is supported by $182.5M in cash and improved operating cash flows, but revenue-interest financing remains a material risk.

Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in September:

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals' revised FY 2026 revenue outlook of $310 million -- $325 million came in below the roughly $332 million -- $334 million analysts were modeling, and PHAT shares sold off on the news Phathom Pharmaceuticals' revised FY 2026 revenue outlook of $310 million -- $325 million came in below the roughly $332 million -- $334 million analysts were modeling, and PHAT shares sold off on the news

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)

PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)

NEW YORK--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) shareholders took losses after the Company lowered its full-year 2026 revenue guidance to $310 million–$325 million from its previously issued $320 million–$345 million range, falling below Wall Street consensus estimates of approximately $332 million. If you suffered a loss on your Phathom Pharmaceuticals investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via.

PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript

Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals guided FY 2026 revenue as high as $345 million while building out a sales force of more than 290 representatives. The revised outlook now tops out at $325 million, and PHAT shareholders absorbed the decline.

Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals Q2 Earnings Call Highlights

Phathom Pharmaceuticals NASDAQ: PHAT reported second-quarter 2026 revenue growth of 88% year over year and said it achieved positive operating profit excluding stock-based compensation for the first time in its history, reaching the milestone one quarter ahead of its prior plan.

Phathom Pharmaceuticals Q2 Earnings Call Highlights

Zacks Investment Research

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2

Phathom Pharmaceuticals, Inc. (PHAT) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.79 per share a year ago.

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

See News Rankings

Price charts implemented using Lightweight Charts™